Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.
William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.
Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.
Jaffer Ajani, MD, of The University of Texas MD Anderson Cancer Center, discusses the importance of HER2/neu testing and other aspects of treating patients with advanced gastroesophageal adenocarcinoma.
Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.
Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center, discusses ways to prevent advanced-phase chronic myeloid leukemia through adherence to prescribed treatment and routine monitoring of disease burden.
